We are proud to announce the FDA-approval of Detomidine Hydrochloride (ANADA 200-674), the first FDA-approved generic detomidine hydrochloride injection (10mg/mL) This product follows last year’s launches of Medetomidine Hydrochloride (ANADA 200-610), the first FDA-approved generic medetomidine hydrochloride injection (1mg/mL) and Revertidine (ANADA 200-624), the first FDA-approved generic atipamezole hydrochloride injection (5mg/mL). We are excited to have now launched three of our most successful Canadian products into the U.S. Market. These FDA registrations showcase the regulatory expertise of our young company and our strong commitment to expand our presence in the US market. Refer to the FDA-CVM update: https://www.fda.gov/animal-veterinary/cvm-updates/fda-approves-first-generic-detomidine-hydrochloride-injectable-solution-horses
